Richard Anthony Flynn

Title: The Innovations of Richard Anthony Flynn in Pharmaceutical Compositions

Introduction

Richard Anthony Flynn, based in Kent, UK, is a notable inventor recognized for his contributions in the pharmaceutical field. With a focus on enhancing drug delivery methods, Flynn has garnered attention in the medical community. His innovative work aims to improve treatment options for patients with specific ailments, showcasing his commitment to finding practical solutions.

Latest Patents

Flynn holds a patent for "Micronized colistimethane sodium pharmaceutical compositions." This innovative formulation describes micronized powder particles of colistimethate sodium, where at least 50% by volume of the particles measure less than 7 micrometers but no less than 3 micrometers. The total moisture content of the powder ranges from 5 to 10% by weight. These micronized particles are particularly beneficial for treating pulmonary infections through powder inhalation, specifically targeting infections caused by gram-negative bacteria and benefiting patients suffering from cystic fibrosis.

Career Highlights

Currently employed at Actavis Group Ptc Ehf, Flynn has made significant contributions to the realm of pharmaceutical sciences. His work has emphasized the need for innovative drug formulations, contributing to effectiveness in treating complex bacterial infections. Flynn's unique approach to drug development showcases his deep understanding of pharmaceutical needs.

Collaborations

Richard Flynn collaborates with esteemed colleagues such as Rahul Surana and Anil Chhettry, who have also played vital roles in advancing pharmaceutical innovations. Their combined expertise fosters a dynamic environment for research and development, allowing for a cross-pollination of ideas that drives impactful discoveries.

Conclusion

Richard Anthony Flynn's inventive work in micronized pharmaceutical compositions marks a significant advancement in the treatment of pulmonary infections, particularly for individuals with cystic fibrosis. His patent illustrates not only his ingenuity but also a profound understanding of the complexities in pharmaceutical development. As he continues to innovate within the industry, the impact of his contributions will surely resonate through improved patient care and medical advancements.